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In 1938, Gutman et al. (6) described increased 
levels of acid phosphatase in metastatic carcinoma 
of the prostate. Since then, when most of us hear 
the term "acid phosphatase" we immediately think 
of prostatic cancer, and justifiably so. The link, how-
ever, between the test and the diagnosis is not as 
clear and simple as many of us would like to believe. 
I would first like to discuss this enzyme, re-
viewing some of its chemistry, its clinical value and 
the pitfalls and problems associated with the routine 
tests. Then I would like to tell about some work 
in which we have been involved that we hope will 
increase the diagnostic value of this enzyme and 
perhaps point the way to advances in clinical enzy-
mology in other areas. 
Chemical Assays. First let us remember that 
the term "acid phosphatase" simply means an enzyme 
which, at pH below 7 .0, hydrolyzes phosphate esters 
liberating the phosphate ion and replacing it with 
an -OH group. Prostatic acid phosphatase is only 
one of many enzymes in this category. The organic 
portion of the phosphate ester involved is not speci-
fically defined by the term acid phosphatase, and this 
brings up our first problem. We do not know the 
natural physiological substrate of prostatic acid 
phosphatase. Indeed we know very little about the 
biological function of this enzyme. Consequently, we 
must measure its activity using synthetic phosphate 
esters which are, as far as we know, completely 
unrelated to prostatic physiology and reproduction. 
Each new substrate gives rise to a new assay, a new 
set of units, new degrees of specificity and sensitivity 
and new problems of interpretation. 
As previously mentioned, there are many forms 
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of this enzyine which are not derived from the 
prostate. Indeed, it is present to some degree in 
virtually all tissues as a lysosomal enzyme. In blood 
chemistry, however, the most common source of non-
prostatic acid phosphatase is the red blood cell. For 
this reason several clinical assays have been de-
veloped which readily differentiate between prostatic 
and erythrocytic acid phosphatase. Table 1 lists the 
methods and substrates commonly employed in the 
clinical laboratory. The Bodansky ( 4) and Babson-
Read (2) as well as the newer thymolphthalein 
phosphate method described by Roy, Brower, and 
Hayden ( 14) will not detect red cell acid phospha-
tase. The King-Armstrong (7) and Bessey-Lowry 
( 3) methods will detect the red cell enzyme, how-
ever, and employ an inhibitor, usuall:r L( +) tartrate, 
to differentiate prostatic and erythrocytic acid phos-
phatase. Table 2 lists inhibitors which can be used 
for this purpose. Although selective substrates and 
inhibitors can make this distinction, it should be 
emphasized that they do not provide a truly specific 
test for prostatic acid phosphatase. Indeed, ~-glycero-
phosphate and a-naphthyl phosphate are histochemi-
cal substrates (7) commonly employed for staining 
acid phosphatase in a variety of tissues. 
For tissue analysis and for occasional patho-
logical sera, inhibitors and substrate selectivity do not 
clearly distinguish between prostatic and rion-
prostatic acid phosphatase. Table 3 lists some of 
the nonprostatic diseases which have been reported 
to cause elevations in serum acid phosphatase and 
while they rarely present a problem of differential 
diagnosis in carcinoma of the prostate, we should 
not ignore their existence. 
A far more common problem is the interpreta-
tion of serum acid phosphatase levels where the en-
zyme is of prostatic origin and where we are con-
cerned with the diagnosis and staging of prostatic 
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TABLE 1. 
METHOD SUBSTRATE PROSTATE RBC 
Bodansky 13-Glycerophosphate ii 
King-Armstrong Phenyl phosphate ii ii 
Bessey-Lowry p-Nitrophenylphosphate ii ii 
Babson-Read a-Naphthyl phosphate ii 
Roy-Brower- Thymolphthalein 
Hayden phosphate ii 
cancer. Most prostatic carcinomas produce this en-
zyme, and low serum levels in the face of apparent 
widespread diseases are usually the result of heat 
denaturation at neutral or alkaline pH as this enzyme 
rapidly loses its activity if the serum sample is not 
acidified and refrigerated. 
An elevated serum prostatic acid phosphatase in 
general suggests prostatic cancer which has extended 
beyond the prostate; however, prostatic surgery, 
diagnostic palpation, and prostatic infarction may 
cause transient enzyme elevations. Careful attention 
to the time when the sample is drawn and to speci-
men handling will greatly improve the reliability of 
routine serum assays. 
Immunology. In order to provide a highly spe-
cific means of diagnosing prostatic cancer, we began 
investigating the antigenicity of prostatic tissue and 
secretions first iIT dogs ( 8) and later in man ( 10, 11). 
Using antisera raised in rabbits immunized with dog 
prostatic fluid or human sperm-free ejaculate we 
could demonstrate an immunological organ speci-
ficity of prostatic acid phosphatase. This specificity 
had also been observed by Shulman and his co-
workers ( 15) and has been confirmed by several 
other investigators ( 12, 13). Our methods of demon-
strating antiprostatic acid phosphatase involved re-
acting the antisera with prostatic homogenate in an 
Ouchterlony agar gel immunodiffusion system. After 
precipitin lines formed, the gel was washed and 
stained histochemically for acid phosphatase (14). 
TABLE 2. 
INHIBITOR PROSTATE RBC 
Ethyl alcohol 40% . . . . . . . . . . . . . . . . . ( +) ( - ) 
L (+)tartaric acid 0.02 M. . . . . . . . . . . ( +) ( - ) 
Formaldehyde 2% . . . . . . . . . . . . . . . . ( - ) ( +) 
Cupricion0.001 M... ... . . . . . .... . (-) (+) 
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TABLE 3. 
NON·PROSTATIC CAUSES OF ELEVATED ACID PHOSPHATASE 
Gaucher's disease 
Osteitis deformans 
Thrombocythemia 
Lipid histocytosis 
Hemorrhagic shock 
Lymphoblastic leukemia 
Nonprostatic carcinoma 
Extensive absorption of the antisera with non-
prostatic tissues confirmed the tissue specificity of 
both dog and human prostatic acid phosphatase. 
Antihuman prostatic acid phosphatase was then 
raised against a partially purified enzyme prepara-
tion. Human sperm-free ejaculate was passed 
through an ion-exchange column packed with DEAE 
Sephadex ( A-50) equilibrated with 0.1 M Tris-HCI 
pH 8.0. Acid phosphatase was trapped in the column 
while most other seminal proteins passed through 
freely. The enzyme was then eluted with a sodium 
chloride molarity gradient, concentrated by ultra-
filtration and used with complete Freund's adjuvant 
to immunize New Zealand White rabbits (15). This 
antiserum was also checked by Ouchterlony im-
munodiffusion together with a diazo coupling stain 
for acid phosphatase as described previously ( 15). 
The serum was tested against prostate, liver, spleen, 
kidney, pancreas, salivary gland, gastric mucosa; 
large and small bowel, breast, lung, muscle, lymph 
node, heart and freshly prepared packed platelets. 
The only positive reaction was with prostatic acid 
phosphatase. Antiserum of this quality can be used 
to specifically identify and quantitate the prostatic 
enzyme. 
The sensitivity of gel diffusion tests is too low 
to detect normal or moderately elevated serum acid 
phosphatase; however, these simple, inexpensive 
tests can be used to identify prostatic cancer since 
the tissue itself is usually quite rich in the enzyme. 
Clinical Study. A logical application of such a 
test would seem to be the identification of prostatic 
carcinoma in bone marrow as the tumor charac-
teristically spreads to bone artd the presence of bony 
metastases is a critical factor in staging the disease. 
In order to compare the concentration of prostatic 
acid phosphatase in bone marrow with that in serum, 
quantitative radial immunodiffusion plates were pre-
pared by incorporating the antiserum in 1.5 % agar 
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Fig. 1-Serial dilution of prostatic acid phosphatase showing reduction of precipitive ring with decreasing enzyme concentration. 
s 
A 
Fig. 2-Comparative immunodiffusion results. M = marrow 
well, S = serum well. 
A. Negative reaction in control patient with hematological 
disorder. 
0 
c 
Fig. 2-C. Negative reaction in patient with metastatic pros-
tatic cancer and marked elevation in serum acid phospha-
tase. The rings are of equal size and do not prove the 
presence of tumor in the marrow. 
1,. M) 
... .,,, 
E 
Fig. 2-E. Negative reaction in the patient with benign pros-
tatic hyperplasia and elevated serum acid phosphatase fol-
lowing transurethral resection. No precipitive ring is formed 
around the marrow well. 
s 
Fig 2-B. Positive reaction in metastatic prostatic cancer and 
slightly elevated serum acid phosphatase. No precipitive ring 
has formed around the serum well. 
0 
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Fig. 2-D. Positive reaction in patient with metastatic pros-
tatic cancer and very high serum acid phosphatase . The much 
larger marrow ring proves tumor in the marrow. 
M 
F 
Fig. 2-F. Negative reaction in patient with Gaucher's dis-
ease, elevated serum acid phosphatase and Gaucher's cells 
in the marrow sample. The antiserum does not precipitate 
nonprostatic acid phosphatase. 
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at a concentration of 1: 100. This technique was 
based on the method developed for the quantitation 
of serum immunoglobulins ( 16) . Low levels of en-
zyme produced small red precipitin rings when 
stained for acid phosphatase. As the enzyme concen-
tration was increased the ring diameter increased 
(fig. 1). Bone marrow aspirates and serum samples 
were obtained in the course of routine hematological 
evaluation of 61 patients with prostatic cancer and 
32 patients with benign prostatic disease, nonpros-
tatic neoplasms, or hematological disorders, includ-
ing one patient with Gaucher's disease. Marrow 
smears were stained with Wright-Giemsa and 
screened for tumor cells. Paired smears stained for 
acid phosphatase were also used to screen for pros-
tatic cancer cells. Comparative radial immunodif-
fusion was carried out on quantitative gel plates with 
two sample wells. Serum was placed in one well and 
marrow in the other and diffusion carried out at 
room temperature for 24 hours. The plates were then 
washed and stained. If the precipitin ring around 
the marrow well was larger than that of the serum, 
the test was considered positive. If no ring occurred 
around the marrow well or if serum and marrow 
produced rings of equal diameter, the test was con-
sidered negative for bony metastases (fig. 2A-F). 
Results of Bony Marrow Study. Malignant cells 
were seen in three of the control group and Gauch-
er's cells in one. Only the Gaucher's cells were 
stained by the phosphatase reaction. None of the 32 
controls was positive by immunodiffusion. One pa-
tient with benign prostatic hyperplasia who was 
studied immediately after cystoscopy showed detect-
able serum prostatic acid phosphatase but no detect-
able enzyme in the marrow, thus documenting a 
serum elevation due to prostatic manipulation. 
Among the 61 patients with prostatic cancer, 12 had 
malignant cells in their marrow and gave a positive 
immunodiffusion test. Four other cases of prostatic 
carcinoma were positive by immunodiffusion; how-
ever, no tumor cells were found in the marrow 
aspirates. All four of these patients had bony lesions 
by x-ray. 
These data suggest that a comparative im-
munoassay for prostatic acid phosphatase may pro-
vide a simple, inexpensive yet specific means of 
establishing that a patient has carcinoma of the 
prostate in an advanced stage. In two cases, we have 
obtained positive immunodiffusion tests on men with 
carcinoma of undetermined primary. Both of these 
were subsequently proven to have prostatic cancer. 
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While we have only applied this technique clinically 
on bone marrow aspirates, autopsy studies indicate 
that it is equally successful in identifying prostatic 
cancer in lymph nodes and other nonprostatic 
organs. 
It is our belief that the techniques applied here 
to prostatic cancer could be extended to other neo-
plasms which continue to produce some tissue spe-
cific substance. Ultimately, a large battery of antisera 
might be developed which could be employed for 
identifying neoplasms and for immunochemical stag-
ing of these diseases. The antigenic specificity of 
enzymes and other cellular products provides a new 
parameter for clinical laboratory testing which should 
lead to improved diagnostic procedures in both neo-
plastic and non-neoplastic diseases. 
Author's note: The immunological studies de-
scribed in the above article were accomplished in a 
cooperative study carried out by Drs. Charles L. 
Johnston, Jr., M. J. V. Smith, Warren W. Koontz, 
Jr. and the author. 
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